| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14728214.2013.805203 |
| P698 | PubMed publication ID | 23725567 |
| P2093 | author name string | David H Ilson | |
| Geoffrey Y Ku | |||
| P2860 | cites work | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| Cancer statistics, 2013 | Q27860762 | ||
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| The biology of vascular endothelial growth factor | Q29615946 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial | Q29620127 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Molecular determinants in targeted therapy for esophageal adenocarcinoma | Q33243542 | ||
| Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer | Q33374495 | ||
| Phase II study of sunitinib as second-line treatment for advanced gastric cancer | Q33389519 | ||
| Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract | Q33458312 | ||
| Transhiatal esophagectomy: clinical experience and refinements | Q33736453 | ||
| Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. | Q33990928 | ||
| Growth factor receptor tyrosine kinases | Q34164164 | ||
| The HER-2/neu oncogene in tumors of the gastrointestinal tract | Q34311106 | ||
| A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer | Q44902236 | ||
| A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. | Q45023409 | ||
| Gefitinib--a novel targeted approach to treating cancer | Q45169148 | ||
| Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer | Q46119167 | ||
| Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response | Q46322646 | ||
| A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma | Q46896374 | ||
| A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response | Q46972228 | ||
| Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. | Q51779657 | ||
| Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors | Q52297317 | ||
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 | ||
| Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. | Q54483761 | ||
| Esophageal Cancer | Q56209683 | ||
| Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer | Q57259796 | ||
| Amplification and over-expression of theEGFR anderbB-2 genes in human esophageal adenocarcinomas | Q57421139 | ||
| Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review | Q34631121 | ||
| A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus | Q35050662 | ||
| Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). | Q35134370 | ||
| Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer | Q35565614 | ||
| Association of HER2/ErbB2 expression and gene amplification with pathologic features and prognosis in esophageal adenocarcinomas | Q35681702 | ||
| Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma | Q35761590 | ||
| Role of HER receptors family in development and differentiation. | Q35837065 | ||
| Vascular endothelial growth factor in esophageal cancer | Q35849980 | ||
| Epidemiology of upper gastrointestinal malignancies | Q35857418 | ||
| Molecular biology of upper gastrointestinal malignancies | Q35857426 | ||
| Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum. | Q35927364 | ||
| Molecular biology of esophageal cancer in the genomics era. | Q36146169 | ||
| MicroRNA expression profiles of esophageal cancer | Q36490960 | ||
| Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma | Q36510119 | ||
| Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer | Q36614881 | ||
| Expression of angiogenic factors predicts response to chemoradiotherapy and prognosis of oesophageal squamous cell carcinoma | Q36644051 | ||
| The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review | Q36650719 | ||
| Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas | Q36869621 | ||
| Oncogene addiction | Q37152445 | ||
| Oncogenic pathway combinations predict clinical prognosis in gastric cancer. | Q37357165 | ||
| Novel agents on the horizon for cancer therapy | Q37412798 | ||
| Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. | Q37449181 | ||
| Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. | Q38030442 | ||
| Sequential infusional 5-fluorouracil followed by concomitant radiation for tumors of the esophagus and gastroesophageal junction | Q39536782 | ||
| HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells | Q39922969 | ||
| Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death | Q40068228 | ||
| Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. | Q40337878 | ||
| Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma | Q40559629 | ||
| Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. | Q40667282 | ||
| HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma | Q40779159 | ||
| A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer | Q43222301 | ||
| Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study | Q43264239 | ||
| Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial | Q43712233 | ||
| Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus | Q43988072 | ||
| A Pilot Phase II Study of Capecitabine in Advanced or Recurrent Gastric Cancer | Q44405286 | ||
| Carcinoma of the esophagus in India | Q44524721 | ||
| Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer | Q44774945 | ||
| Neoadjuvant Cis-DDP in esophageal cancers: an experience at a regional cancer centre, India | Q44892240 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 219-230 | |
| P577 | publication date | 2013-06-01 | |
| P1433 | published in | Expert Opinion on Emerging Drugs | Q5421207 |
| P1476 | title | Emerging tyrosine kinase inhibitors for esophageal cancer | |
| P478 | volume | 18 |
| Q52682256 | Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis. |
| Q38968846 | ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways |
| Q26865552 | Esophageal cancer: Recent advances in screening, targeted therapy, and management |
| Q36738988 | Griffipavixanthone, a dimeric xanthone extracted from edible plants, inhibits tumor metastasis and proliferation via downregulation of the RAF pathway in esophageal cancer |
| Q40784649 | Subcellular localization of EGFR in esophageal carcinoma cell lines |
| Q26852061 | Surgery in the era of the 'omics revolution |
| Q64232973 | Time profile of nimotuzumab for enhancing radiosensitivity of the Eca109 cell line |
Search more.